

***Amendments to the Claims***

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (currently amended)      A method for inhibiting cancerous growth of a mammalian breast cancer cell that expresses EphB4, or a mammalian colon cancer cell that expresses EphB4, the method comprising

contacting said cell with at least one antibody or an antigen-binding portion thereof, wherein said antibody or antigen-binding portion thereof binds an EphB4 epitope located within residues 200 to 400 of EphB4 (SEQ ID NO:1),

binding said antibody or said antigen-binding portion thereof to said cell's EphB4, and

inhibiting said cancerous growth as a result of said binding.

2. (previously presented)      The method according to claim 1, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO:1).

3. (previously presented)      The method according to claim 2, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 244 of EphB4 (SEQ ID NO:1).

4. (previously presented) The method according to claim 3, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 230 of EphB4 (SEQ ID NO:1).

5. (previously presented) The method of claim 1, wherein said cell is a human cell.

6. - 7. (canceled)

8. (currently amended) A method for inducing cell death of a mammalian breast cancer cell that expresses EphB4, or a mammalian colon cancer cell that expresses EphB4, the method comprising

contacting said cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds an EphB4 epitope located within residues 200 to 400 of EphB4 (SEQ ID NO:1),

binding said antibody or said antigen-binding portion thereof to said cell's EphB4, and

inducing said cell death as a result of said binding.

9. (previously presented) The method according to claim 8, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO:1).

10. (previously presented) The method according to claim 9, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 244 of EphB4 (SEQ ID NO:1).

11. (previously presented) The method according to claim 10, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 230 of EphB4 (SEQ ID NO:1).

12. (previously presented) The method of claim 8, wherein said cell is a human cell.

13.-14. (canceled)

15. (currently amended) A method for treating ~~or preventing~~ breast cancer ~~or colon cancer~~ in a mammalian subject, wherein said subject is in need of the inhibition of growth, or inducing the cell death of, of breast cancer cells, or colon cancer cells, that express EphB4,

the method comprising

administering to the subject an effective amount of at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO:1),

contacting said antibody or said antigen-binding portion thereof with said cell as a result of said administering,

binding said antibody or said antigen binding portion thereof to said cell's EphB4 thereby inhibiting said growth of, or inducing the cell death of, said cancer cells, and treating or preventing said cancer in said subject as a result of said binding.

16. (previously presented) The method according to claim 15, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO:1).

17. (previously presented) The method according to claim 16, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 244 of EphB4 (SEQ ID NO:1).

18. (previously presented) The method according to claim 17, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 230 of EphB4 (SEQ ID NO:1).

19. (currently amended) The method method of claim 15, wherein said subject is human.

20.-38. (canceled)

39. (previously presented) The method of any one of claims 1, 8 and 15, wherein the amino acid sequence of said cell's EphB4 comprises that of amino acids 200-400 of SEQ ID NO:1.

40.-44 (canceled)

45. (previously presented) The method of any one of claims 1, 8 and 15, wherein said antibody is a monoclonal antibody.